
Need Support?

Florida labs billing First Coast Service Options face a maze of 2026 changes: coding rules are now present in separate articles, not LCDs, requiring constant cross-checking. Referring lab claims demand precise Modifier 90 use, split paper submissions, and strict attestation. New quarterly CLFS rates and updated molecular pathology policies add more complexity.
To stay compliant, labs must verify current billing articles, update fee schedules quarterly, correctly split referred and non-referred claims, and ensure CLIA numbers are populated. A dedicated Florida lab billing partner, like TransLabs, that tracks FCSO policy shifts embeds these checks into daily workflow, preventing denials and protecting revenue so your team can focus on accurate testing.
Running a diagnostic lab isn’t easy when Medicare rules shift constantly. If you use laboratory RCM services in Florida, Puerto Rico, or the U.S. Virgin Islands, First Coast Service Options (FCSO) is the entity that runs local coverage. And in 2026, they’ve made some changes you really can’t afford to miss.
Here’s the thing: a single missed modifier or an outdated local coverage determination (LCD) reference can turn a clean claim into a denial. That’s frustrating and costly.
But it’s avoidable. Here, we’ll discuss the latest FCSO LCD updates, the newly revised referring and reference lab rules, and the 2026 Clinical Laboratory Fee Schedule (CLFS) changes, and guide you through what you need to bill clean and get paid on time.
FCSO, the Medicare Administrative Contractor (MAC) for Jurisdiction N, updated its Local and National Coverage Reference Guide in February 2026, and it’s a useful roadmap for anyone billing diagnostic services in the region.
One important thing is that coding rules are no longer listed in the LCD PDFs for CPT or HCPCS codes, but are defined in separate Billing and Coding Articles. FCSO now houses coding guidance, documentation requirements, and modifier information inside standalone (or LCD-linked) articles, each marked with a yellow banner that guides you whether it’s tied to an LCD or stands on its own.
An FCSO LCD includes:
A billing and coding article consists of:
If you can’t find a specific LCD for a service, don’t assume it’s not covered. No LCD doesn’t automatically mean no coverage. It usually just means FCSO hasn’t identified that service as needing a local policy yet, and “reasonable and necessary” guidelines still apply by default.
FCSO refreshed its Referring and Reference Laboratories billing guidance in July 2026, clearing up a lot of confusion around Section 1833(h)(5)(A) of the Social Security Act.
Now, before discussing it further, let’s clear up these terms:
A single lab can function both as a referring or a reference laboratory, depending on the situation. For billing, it’s important to figure out who can bill a claim, which we’ll explore in the next section.
| Scenario | Who Bills |
|---|---|
| Reference lab bills Medicare | Referring lab cannot bill |
| Referring lab bills Medicare | Referring lab must ensure the reference lab doesn't also bill |
| Part B referral claims | Only permitted from independent clinical labs (specialty code 69) |
A referring lab can only bill for tests performed elsewhere if it meets any of these three conditions:
Labs must attest to which condition applies right at enrollment, using FCSO’s Clinical Lab Questionnaire Form. If you miss this step, it leads to a claim denial down the road.
Here’s a mistake billers make constantly: mixing referred and non-referred tests on one paper claim. FCSO clearly mentions that a CMS-1500 form combining both bounces back as unprocessable. You need two separate claims.
| Function | Paper (CMS-1500) | Electronic (837P) |
|---|---|---|
| Billing (referring) lab | Item 33 / 33a | Loop 2010AA |
| Performing (reference) lab | Item 32 / 32a | Loop 2310C |
| Modifier 90 | Item 24D | Loop 2400 SV101 |
| CLIA number | Item 23 | Loop 2400 REF (F4) |
| Additional CLIA (if needed) | N/A | Loop 2300 REF (X4) |
Pro tip: Electronic claims (837P) give you more flexibility since billing and performing lab data are stored separately in the system. If your lab is still leaning heavily on paper submissions, 2026 is a good year to make the switch.
For the first time since 2017, CMS is updating Clinical Laboratory Fee Schedule (CLFS) rates for clinical diagnostic laboratory tests (CDLTs) that aren’t advanced diagnostic laboratory tests (ADLTs). That’s nearly a decade of stagnant rates finally getting a refresh.
Per MM14312, the Calendar Year 2026 Annual Update sets the following:
There is also a quarterly update (CR 14371) effective April 1, 2026, tied to Section 6226 of the Consolidated Appropriations Act of 2026. According to it, rates aren’t static this year. They’re shifting quarter by quarter, so your billing software and fee schedules need to stay current.
And here is something labs must remember. Applicable labs must report private payor rates during the February through April window. If they don’t, CMS may fall back on older benchmarks that don’t reflect current market reimbursement, and that can reduce your reimbursement for years.
CMS also rolled out its January 2026 Laboratory NCD Edit Software update (MM14226), which affects the 23 National Coverage Determinations found in the Medicare NCD Manual, Chapter 1, Part 3, sections 190.12 through 190.34.
These NCDs cover everything from urine cultures to blood counts, and the edit module gets refreshed quarterly to reflect ICD-10-CM code changes. If your claims scrubber isn’t updated to match, you’re likely to see an increase in the number of claim denials for diagnosis codes that should be processed smoothly. While it’s a small technical detail, it quietly drains a lab’s revenue cycle when systems aren’t updated, and new billing laws aren’t monitored.
Genetic testing is one of the fastest-growing (and most scrutinized) areas in lab billing right now. FCSO revised its Billing and Coding: Molecular Pathology and Genetic Testing article (A58918), effective for dates of service on and after April 1, 2026, aligning it with the quarterly CPT/HCPCS code updates.
FCSO also held a webinar in February 2026 covering new and revised LCDs and articles focused on molecular pathology, genetic testing, arterial duplex ultrasound, and botulinum toxin coverage. If your lab runs genetic panels, this is one area where staying a quarter behind can lead to revenue loss. Bookmark FCSO’s news page and read the update history to manage things proactively instead of waiting for a denial.
| Challenge | Root Cause | Fix |
|---|---|---|
| Duplicate billing denials | Both referring and reference lab submit claims | Confirm billing responsibility upfront; use Modifier 90 correctly |
| Claim rejected as unprocessable | Referred and non-referred tests combined on one paper claim | Split into two separate CMS-1500 forms |
| Missing CLIA number | Performing lab's CLIA not reported | Populate Item 23 (paper) or Loop 2400 REF F4 (electronic) |
| Outdated fee schedule | Team using pre-2026 CLFS rates | Cross-check against MM14312 and quarterly CLFS updates |
| Genetic test denial | Coding article revision missed | Review A58918 quarterly for CPT/HCPCS changes |
| "No LCD found" confusion | Assuming absence of LCD means no coverage | Apply reasonable and necessary guidelines by default |
If you’ve never used the Medicare Coverage Database (MCD), here’s a quick walkthrough:
You can also use FCSO’s own Advanced LCD Search Hub for a more localized experience, or their LCD Interactive Index for an alphabetical list of everything currently active.
Heads up: Other MACs’ LCDs show up in the MCD too, so double-check the contractor field before you assume a policy applies to you.
Your lab billing team must create a checklist to make sure that your claims comply with FCSO’s policies. Here are a few questions you must note down and review your billing patterns against these:
If you can check every box, that’s perfect. If not, it indicates the common issue every lab faces when they’re trying to manage tests and billing together. The thing is that billing is a completely different game, which works perfectly only if dedicated staff look at it.
You can excel in it if you outsource the process to Florida laboratory billing service experts, such as TransLabs, which master FCSO policies, stay current with the latest updates, and help you with clean claim submissions, while you focus on performing tests.
Medicare billing rules for labs aren’t constant. 2026 is proving that once again. Between FCSO’s restructured LCD and article framework, the refreshed referring and reference lab guidelines, and the long-awaited CLFS rate update, a lot is moving at once. But here’s the thing: none of it is unmanageable once you know where to look.
Keep an eye on the official FCSO and CMS resources, train your billing staff on Modifier 90 and claim-splitting rules, and build a habit of checking coding articles every quarter instead of once a year. If you do that, it’ll save you time in fighting denials, and you’ll be able to collect what you’re actually owed.